Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...
Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately held back development of a multiple sclerosis drug to avoid payments ...
Fact checked by Katrina Munichiello Reviewed by Somer Anderson What Is a Hostile Takeover? A hostile takeover happens when an acquiring company moves forward with buying another company, the target ...
Genzyme continued to drive growth for Sanofi in the first quarter, helped along by the company’s vaccines unit, but diabetes drugs are still struggling. Net sales were €8,391 million ...
Hosted on MSN1mon
Sanofi CEO believes company poised for growth from new drugsNEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...
Strategic Collaborations: The company's ability to establish and maintain collaborations, such as the prior agreement with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback